Guest: Stephen L. Kopecky, M.D. 

Host: Darryl S. Chutka, M.D. (@ChutkaMD) 

What are the updated guidelines for managing hyperlipidemia and how do the risk modifiers change how patients should be treated? What do you do when a patient starts a statin and there is no change in cholesterol levels? What do you do when increasing the dose or switching to a stronger drug continues to have little to no impact? Dr. Kopecky discusses the updated guidelines, challenges with statin therapy, and additional tactics to consider in treating hyperlipidemia. 

Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Deeper Dive:

• 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines http://www.onlinejacc.org/content/early/2018/11/02/j.jacc.2018.11.003
• Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia https://www.nejm.org/doi/full/10.1056/NEJMoa1812792